Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00436579 · ClinicalTrials.gov registry record · Phase 1
Sorafenib in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
NCT00436579: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00436579 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 110 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00436579, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
Study Summary
This randomized phase I trial is studying the side effects, such as high blood pressure, and best dose of sorafenib in treating patients with advanced solid tumors. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG sorafenib tosylate
- PROCEDURE assessment of therapy complications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2007-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00436579
The ClinicalTrials.gov registry entry for NCT00436579 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00436579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00436579 about?
NCT00436579 is a clinical study titled "Sorafenib in Treating Patients With Advanced Solid Tumors". This randomized phase I trial is studying the side effects, such as high blood pressure, and best dose of sorafenib in treating patients with advanced solid tumors. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the t...
What is the current status of trial NCT00436579?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2007-01.
What interventions are being tested in trial NCT00436579?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), sorafenib tosylate (DRUG), assessment of therapy complications (PROCEDURE).
Who is sponsoring clinical trial NCT00436579?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.